While blood clots are not a documented side effect of Zepbound, patients should be aware of general risk factors for venous thromboembolism that may be present regardless of medication use: Obesity itself (BMI 30 kg/m) Prolonged immobility (long flights, bed rest, sedentary lifestyle) Prior history of DVT or PE Active malignancy or recent surgery Recent hospitalization or major trauma Pregnancy or postpartum period Oral contraceptive or hormone replacement therapy use Inherited or acquired thrombophilia (Factor V Leiden, antiphospholipid syndrome) Smoking Advanced age Warning signs of deep vein thrombosis (DVT) include: Unilateral leg swelling, pain, or tenderness (often in the calf) Warmth and redness over the affected area Heaviness or aching in the leg Warning signs of pulmonary embolism (PE) include: Sudden onset of shortness of breath or difficulty breathing Sharp chest pain that worsens with deep breathing or coughing Rapid heart rate or palpitations Coughing up blood (hemoptysis) Lightheadedness, dizziness, or syncope Anxiety Patients starting Zepbound should maintain adequate hydration, remain physically active as tolerated, and avoid prolonged periods of immobility
Hayes JD, Dinkova-Kostova AT
A clean Certificate of Analysis from the supplier is not the same as an independent third-party assay, and almost no buyer is in a position to audit the difference
Pdr3 induces the expression of the OMM Cis1 protein, which binds to the translocase TOM70 and recruits AAA-ATPase Msp1 to the translocase
